Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab
Paolo Ghia(Vita-Salute San Raffaele University), Mazyar Shadman(University of Washington), Andy H. Szeto(National University of Misiones), Keri Yang(Universidad San Carlos), Jason C. Paik, Brad S. Kahl(UW Health University Hospital), Gisoo Barnes, Tadeusz Robak(Medical University of Lodz), Jennifer R. Brown(Dana-Farber Cancer Institute), Tian Tian(Harbin Medical University), Constantine S. Tam(The Alfred Hospital)
Cited by 3
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k